Weekly Analysts’ Ratings Changes for Vir Biotechnology (VIR)

Several brokerages have updated their recommendations and price targets on shares of Vir Biotechnology (NASDAQ: VIR) in the last few weeks:

• 1/13/2025 – Vir Biotechnology had its price target raised by analysts at Leerink Partners from $18.00 to $20.00. They now have an “outperform” rating on the stock.
• 1/10/2025 – Vir Biotechnology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
• 1/9/2025 – Vir Biotechnology was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $20.00 price target on the stock, up previously from $10.00.
• 1/9/2025 – Vir Biotechnology had its price target raised by analysts at JPMorgan Chase & Co. from $10.00 to $14.00. They now have a “neutral” rating on the stock.
• 11/20/2024 – Vir Biotechnology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
• 11/20/2024 – Vir Biotechnology had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.

Vir Biotechnology Stock Down 2.9 %

VIR traded down $0.30 during trading on Tuesday, reaching $10.22. 1,554,006 shares of the stock traded hands, compared to its average volume of 7,012,080. The stock’s 50-day moving average is $8.26 and its 200 day moving average is $8.36. Vir Biotechnology, Inc. has a 12 month low of $6.56 and a 12 month high of $14.45. The stock has a market capitalization of $1.41 billion, a PE ratio of -2.61 and a beta of 0.51.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The business had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The company’s revenue for the quarter was down 9.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.22) EPS. As a group, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.36 EPS for the current year.

Insider Transactions at Vir Biotechnology

In related news, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total transaction of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares of the company’s stock, valued at $16,431,135.32. This represents a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 14,786 shares of company stock valued at $170,172 in the last quarter. 15.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of VIR. Blue Trust Inc. raised its holdings in shares of Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares during the last quarter. nVerses Capital LLC purchased a new stake in Vir Biotechnology in the third quarter worth $56,000. Magnetar Financial LLC purchased a new position in shares of Vir Biotechnology in the second quarter valued at $95,000. Quest Partners LLC grew its position in shares of Vir Biotechnology by 142.1% in the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after purchasing an additional 7,452 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Vir Biotechnology in the second quarter valued at $119,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).